Wiley Expands its Advanced Journal Portfolio into Life and Health Sciences

Publishing companies rarely make structural bets on entire scientific fields at once. Wiley is doing exactly that. The global academic publisher announced it will add at least eight journals to its Advanced Portfolio by the end of 2026, taking a brand anchored in materials science for over three decades and planting it squarely in life, health, and social sciences.

The move is not simply about adding titles to a catalog. It reflects a strategic calculation: that researchers in biology, medicine, neuroscience, and related disciplines want what chemists and materials scientists have had since the 1990s - a family of journals with coherent editorial standards, strong indexing, and a submission process that does not punish authors for disciplinary ambiguity.

A Single Submission, Multiple Destinations

The defining feature of the Advanced Portfolio is its cross-journal submission model. Authors submit their work once. Professional editors then evaluate which title in the portfolio offers the best fit, routing manuscripts without requiring authors to reformat or restart the submission. For interdisciplinary work - which increasingly describes the most interesting research - this removes one of the most frustrating friction points in scientific publishing.

The portfolio currently spans more than 25 titles. Advanced Materials, launched in 1989, remains its flagship in materials science. Advanced Science, launched in 2014 as an interdisciplinary open-access journal, became the model for the portfolio expansion philosophy. Two AI-focused journals - Advanced Intelligent Discovery and Advanced Robotics Research - joined in 2024. Advanced Chemical Engineering began accepting submissions in January 2026.

The first new title in the life and health sciences expansion is Advanced Oncology, which opens for submissions in March 2026. Its launch coincides with Wiley co-sponsoring the MD Anderson Cancer and Neuroscience Symposium in Houston - a signal that the portfolio is positioning itself within active research communities rather than simply opening a journal and waiting for submissions.

What Drove the Decision

Allyn Molina, Wiley group vice president of publishing development, frames the expansion as a direct response to researcher feedback. Researchers have been asking for more prestigious yet accessible venues for their interdisciplinary work, and the Advanced Portfolio is Wiley's answer: premium options across every field of science.

That feedback points to a real structural problem in scientific publishing. Prestigious journals in life and health sciences are often tightly controlled, with acceptance rates that can fall below 5 percent at the highest-tier titles. Researchers working across disciplinary lines often find their work does not fit cleanly into any single journal's scope. The result is a time-consuming cycle of submission, rejection, and reformatting that can delay publication by months or years.

Kirsten Severing, editor-in-chief of Advanced Science, described the editorial philosophy the expansion aims to carry forward: applying quality, integrity, and interdisciplinary thinking across new fields, making the Advanced Portfolio a natural home for researchers whose work crosses traditional boundaries.

The Market Context

The expansion places Wiley in more direct competition with other multi-journal publishers that have moved aggressively into open-access territory, including Springer Nature's Nature Portfolio and the American Chemical Society's family of journals. It also comes as funding agencies in the United States and Europe increasingly require open-access publication as a condition of grant awards, creating demand for high-quality open-access venues in fields where they have historically been scarce.

The Advanced Portfolio operates on an open-access model, meaning papers become freely available upon publication. Authors typically pay article processing charges, though Wiley has institutional agreements with many universities that reduce or eliminate those fees for affiliated researchers.

The specific titles joining the portfolio beyond Advanced Oncology have not yet been announced. Wiley described them as spanning diverse fields at the intersection of human health, neuroscience, technology, and society, with additional announcements expected in the coming months.

Scale and Trajectory

With more than 200 years of publishing history, Wiley occupies an unusual position: it carries the credibility of a legacy academic publisher while attempting to move quickly enough to compete with newer open-access models. The Advanced Portfolio's expansion into life sciences is its most visible attempt to demonstrate those two things are compatible.

Whether that bet pays off depends largely on editorial execution. Journal reputation in academic science is built over years, through the quality of papers accepted, the rigor of peer review, and the credibility of editors. Eight new titles will need to establish that record from scratch. The Advanced brand provides a foundation, but life sciences researchers have their own established hierarchies of journal prestige that will not shift automatically.

The portfolio's trajectory from materials science specialist to multidisciplinary publisher has been consistent over the past decade. The 2026 expansion is the largest single step in that direction yet.